KalVista Pharmaceuticals Inc (NASDAQ:KALV) released results from the phase 3 KONFIDENT trial demonstrating statistically and clinically significant efficacy of sebetralstat as an oral on-demand ...

Bank of America on Wednesday launched its coverage of KalVista Pharmaceuticals (NASDAQ:KALV) with a Buy recommendation, citing a broad uptake for the company’s lead candidate, sebetralstat.

KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), today announced that Japan’s Ministry of Health, Labour and Welfare (MHLW) has ...

TD Cowen initiated coverage of KalVista (KALV) with a Buy rating and $30 price target The firm cites sebetralstat’s opportunity as the first oral acute therapy for hereditary angioedema attacks ...

KalVista (KALV) announced that Japan’s Ministry of Health, Labour and Welfare, or MHLW, has granted sebetralstat orphan drug designation. The ...

BofA initiated coverage of KalVista (KALV) with a Buy rating and $22 price target The company is developing sebetralstat as the potential first oral, on-demand treatment for hereditary angioedema ...

CAMBRIDGE, Mass. & SALISBURY, England, January 08, 2025--(BUSINESS WIRE)--KalVista Pharmaceuticals, Inc. (NASDAQ: KALV) today announced that the compensation committee of KalVista’s board of ...

KalVista Pharma has filed its first marketing application to the US FDA, seeking approval for its oral plasma kallikrein inhibitor sebetralstat as an oral treatment for hereditary angioedema (HAE ...

KalVista Pharmaceuticals, Inc. is a clinical stage pharmaceutical company, which engages in the discovery, development, and commercialization of small molecule protease inhibitors for diseases ...

January 16, 2025, 04:48 am ET, BY Robert S.- Contributor| Editor: Thomas H. Kee Jr. ( Follow on LinkedIn) Short KALV slightly ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...